CAS: 1185763-69-2; 6-((6-(1-Methyl-1H-Pyrazol-4-yl)Imidazo[1,2-B]Pyridazin-3-yl)Methyl)Quinoline

上下游产品

(rac)-[6-(1-methyl-1H-pyrazol-4-yl)-imidazo[1,2-b]pyridazin-3-yl]-quinolin-6-yl-methanol

📜(Rac)-[6-(1-Methyl-1H-Pyrazol-4-yl)-Imidazo[1,2-B]Pyridazin-3-Yl]-Quinolin-6-Yl-Methanol置于碘,次磷酸,溶剂黄146体系中,用 水 用作溶剂,化学反应 0.5H,反应生成6-[[6-(1-甲基-1H-吡唑-4-基)咪唑并[1,2-B]哒嗪-3-基]甲基]喹啉
参考文献: Imidazo [1,2-B] Pyridazine Derivatives For The Treatment Of C-Met Tyrosine Kinase Mediated Disease[fr] Dérivés D'Imidazo[1,2-B]Pyridazine Pour Le Traitement De Maladies Médiées Par La Tyrosine Kinase C-Met
标题: Imidazo [1,2-B] Pyridazine Derivatives For The Treatment Of C-Met Tyrosine Kinase Mediated Disease[fr] Dérivés D'Imidazo[1,2-B]Pyridazine Pour Le Traitement De Maladies Médiées Par La Tyrosine Kinase C-Met
摘要:该发明涉及式(I)化合物及其盐,式(I)中取代基如规范中所定义,式(I)化合物在用于治疗人体或动物体内的过程中的应用,特别是涉及c-Met酪氨酸激酶介导的疾病;式(I)化合物用于制造治疗此类疾病的药物;包含式(I)化合物的药物组合物,可选地与组合伙伴一起;式(I)化合物的制备方法.

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.